Search
Semaglutide Treatment Options for Weight Loss
A collection of 71 research studies in Weight Loss where Semaglutide is the interventional treatment. Semaglutide is used for conditions such as Weight Loss.
61 - 71 of 71
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Weight Loss
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
GLP-1 Medications for Weight Loss Now Available!
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Studying an Investigational Virus Vaccine
Recruiting
The main objectives of this study are to assess the safety and effectiveness of an investigational vaccine aimed at preventing norovirus, commonly known as the stomach flu. Participants will be randomly assigned to receive either the investigational vaccine or a placebo. Should you express interest, you will be contacted directly by the research site, which will provide further details and answer any questions you may have about study requirements, risks/benefits, and any compensation.
Conditions:
Healthy
Interested in vaccine studies
All Conditions
Preventative Trials
Featured Trial
Type 2 Diabetes Clinical Trial
Recruiting
Can changing your breakfast improve your type 2 diabetes? If you have an HbA1C of 7.0% or higher, you are invited to participate in an online study at the University of Michigan.
Conditions:
Type 2 Diabetes
Diabetes Mellitus Type 2 in Obese
Diabetes Type Two
Type 2 Diabetes Mellitus
Diabete Type 2
Research Study to Investigate How Well Semaglutide Works Compared to Liraglutide in People Living With Overweight or Obesity
Completed
This study will look at participants' body weight from the start to the end of the study. The study will last for about 1½ years. This is to compare the effect on body weight in people taking semaglutide once a week or people taking liraglutide once every day. Participants will either get semaglutide, liraglutide or "dummy" medicine. Which treatment is decided by chance. Participants who receive semaglutide or semaglutide "dummy" medicine will need to take 1 injection once a week. Participants w... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/18/2023
Locations: Novo Nordisk Investigational Site, Birmingham, Alabama +18 locations
Conditions: Overweight, Obesity
Once Weekly GLP-1 in Persons With Spinal Cord Injury
Completed
Chronic spinal cord injury (SCI) results in adverse soft tissue body composition changes and an extremely sedentary lifestyle. These abrupt changes often lead to a high prevalence of cardiometabolic diseases, such as impaired glucose tolerance/diabetes mellitus and dyslipidemia, conditions which predispose those with SCI to an increased risk for cardiovascular disease compared to the general population. Due to paralysis and wheel chair dependence, maintaining an adequate level of physical activi... Read More
Gender:
ALL
Ages:
Between 18 years and 69 years
Trial Updated:
03/10/2023
Locations: Kessler Institute for Rehabilitation, West Orange, New Jersey
Conditions: Spinal Cord Injuries, Insulin Resistance, Pre Diabetes, Obesity
Semaglutide to Reduce Atrial Fibrillation Burden
Suspended
Atrial fibrillation (AF) is the most common arrhythmia worldwide. AF is associated with obesity and the co-morbidities of obesity, including hypertension and obstructive sleep apnea (OSA) which increase left atrial (LA) size and decrease LA function. Semaglutide, a Glucagon-like peptide receptor 1 agonist (GLP-1 RA), is currently approved by the Food and Drug Administration for weight loss for individuals with and without diabetes. The effects of pharmacologic weight loss with Semaglutide on AF... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/24/2022
Locations: Veterans Affairs Medical Center San Francisco, San Francisco, California
Conditions: Atrial Fibrillation, Obesity, Overweight
Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity
Completed
This study will look at the change in participant's body weight from the start to the end of the study. This is to compare the effect on body weight in people taking semaglutide (a new medicine) and people taking "dummy" medicine. In addition to taking the medicine, the participant will have talks with study staff about healthy food choices, how to be more physically active and what a participant can do to lose weight.
The participant will get semaglutide for the first 20 weeks. Then the partic... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/07/2022
Locations: Novo Nordisk Investigational Site, Anniston, Alabama +71 locations
Conditions: Metabolism and Nutrition Disorder, Obesity
STEP 1: Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity
Completed
This study will look at the change in participants' body weight from the start to the end of the study. The weight loss in participants taking semaglutide (a new medicine) will be compared to the weight loss of participants taking "dummy" medicine. In addition to taking the medicine, participants will have talks with study staff about healthy food choices, how to be more physically active and what you can do to lose weight. Participants will either get semaglutide or "dummy" medicine - which tre... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/18/2021
Locations: Novo Nordisk Investigational Site, Anniston, Alabama +127 locations
Conditions: Metabolism and Nutrition Disorder, Overweight or Obesity
A Research Study of How NNC0174-0833 Taken With Semaglutide Works in People Who Are Overweight or Obese
Completed
The aim of this study is to find out how NNC0174-0833 taken with semaglutide works in people who are overweight or obese. Both study medicines have been investigated on their own. The study also looks at how the study medicines behave in participant's body and how they are removed from the participant's body. Participants will get 1 of the following 2 treatments - which treatment any participant gets is decided by chance: Semaglutide (a new medicine) and NNC0174-0833 (a potential new medicine),... Read More
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
11/16/2021
Locations: Novo Nordisk Investigational Site, Overland Park, Kansas
Conditions: Obesity, Overweight
Research Study to Look at How Well Semaglutide is at Lowering Weight When Taken Together With an Intensive Lifestyle Program
Completed
This study will look at the change in participant's body weight from the start to the end of the study. This is to compare the effect on body weight in people taking semaglutide (a new medicine) and people taking "dummy" medicine. Together with the medicine, the participant will also be part of an intensive lifestyle program where the participant will have talks with study staff about healthy food choices, what the participant can do to lose weight and be more physically active. The participant... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/10/2021
Locations: Novo Nordisk Investigational Site, Birmingham, Alabama +40 locations
Conditions: Overweight, Obesity
Research Study Investigating How Well Semaglutide Works in People With Type 2 Diabetes Suffering From Overweight or Obesity
Completed
This study will look at the change in the participant's body weight from the start to the end of the study. This is to compare the effect on body weight in people taking semaglutide (a new medicine) and people taking "dummy" medicine. In addition to taking the study medicine, the participant will have talks with study staff about healthy food choices, how to be more physically active and what else the participant can do to lose weight. Overweight and obesity is associated with an increased risk... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/08/2021
Locations: Novo Nordisk Investigational Site, Buena Park, California +146 locations
Conditions: Obesity, Overweight
A Research Study of NNC0165-1562 and Semaglutide in People Who Are Overweight or Obese
Completed
The study is investigating new medicines for weight control in people with high body weight. The study looks at how the study medicines work in the body. Participants will get semaglutide and either NNC0165-1562 or "dummy" medicine -which treatment participants get is decided by chance. Participants will get 2 injections per week for 5 months. A study nurse at the clinic will inject the medicine with a thin needle in a skin fold in the stomach. The study will last for about 7 months. Participant... Read More
Gender:
ALL
Ages:
Between 19 years and 55 years
Trial Updated:
07/01/2021
Locations: Novo Nordisk Investigational Site, Tempe, Arizona +1 locations
Conditions: Metabolism and Nutrition Disorders, Overweight or Obesity
Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus
Completed
This trial is conducted globally. The aim of this trial is to investigate safety and efficacy of once-daily semaglutide in obese subjects without diabetes mellitus.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/14/2020
Locations: Novo Nordisk Investigational Site, Anaheim, California +73 locations
Conditions: Metabolism and Nutrition Disorder, Obesity
A Research Study of NNC0165-1875 Alone or Together With Semaglutide in People Who Are Overweight or Obese
Completed
The study is looking at possible new medicines for weight control in people with high body weight. The study looks at how the new medicines work in the body. The study consists of two parts. If participants take part in Part 1, they will either get a single dose of NNC0165-1875 or a "dummy" medicine (placebo). If participants take part in Part 2, they will either get a single dose of NNC0165-1875 or "dummy" medicine and also a single dose of semaglutide. Which treatment participants get is decid... Read More
Gender:
MALE
Ages:
All
Trial Updated:
09/05/2019
Locations: Novo Nordisk Investigational Site, Tempe, Arizona
Conditions: Obesity and Overweight
61 - 71 of 71